Search Result
Results for "
hyperglycemia
" in MedChemExpress (MCE) Product Catalog:
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-121401A
-
(1R)-(−)-Myrtenal; (−)-(1R,5S)-Myrtenal
|
Akt
|
Metabolic Disease
Cancer
|
(−)-Myrtenal ((1R)-(−)-Myrtenal) is an orally active terpene with antitumour activity. (−)-Myrtenal ameliorates hyperglycemia by enhancing GLUT2 through Akt in the skeletal muscle and liver of diabetic rats .
|
-
-
- HY-W010655
-
TAK-875 hemihydrate
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
Fasiglifam (TAK-875) hemihydrate is a potent, selective and orally active GPR40 agonist with EC50 of 72 nM. Fasiglifam enhances glucose-dependent insulin secretion and improves hyperglycemia in type 2 diabetic rats. Fasiglifam can induce liver injury .
|
-
-
- HY-W324220
-
|
11β-HSD
|
Metabolic Disease
|
11β-HSD1-IN-10 (compound c3a) is a potent 11β-HSD1 inhibitor (IC50=1.8 µM for human). 11β-HSD1-IN-10 can be used in studies of obesity, hyperglycemia and cognitive impairment .
|
-
-
- HY-N2953
-
|
Fatty Acid Synthase (FASN)
|
Metabolic Disease
|
Borapetoside E can be isolated from T. crispa. Borapetoside E improves hyperglycemia, insulin resistance, hepatic steatosis, hyperlipidemia, and oxygen consumption in obese mice. Borapetoside E also inhibits SREBPs expression in the liver and adipose tissue .
|
-
-
- HY-W324243
-
|
11β-HSD
|
Metabolic Disease
|
11β-HSD1-IN-9 (compound c4a) is a potent 11β-HSD1 inhibitor with IC50 values of 0.48 and 1.3 µM for human and murine 11β-HSD1, respectively. 11β-HSD1-IN-9 competitively interacts with rat 11β-HSD1. 11β-HSD1-IN-19 can be used in studies of obesity, hyperglycemia and cognitive impairment .
|
-
-
- HY-145157
-
|
Others
|
Others
|
Ferric nitrilotriacetate (Fe-NTA), a complexation of nitriloacetic acid with iron, is a highly reactive compound used to induce degenerative disorders through oxidative stress (OS). Ferric nitrilotriacetate is also used in several studies to induce hyperglycemia, glycosuria, and both renal and liver carcinogenesis .
|
-
-
- HY-147037
-
|
AMPK
|
Cardiovascular Disease
Metabolic Disease
|
AMPK activator 7 (compound I-3-24) is a an AMPK activator with the EC50 of 8.8 nM. AMPK activator 7 can be used for the research of diseases involving AMPK, particularly diseases such as type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and/or hypertension .
|
-
-
- HY-101292
-
|
PPAR
|
Metabolic Disease
|
FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes .
|
-
-
- HY-N3185
-
|
Cholinesterase (ChE)
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
N-Methylcalycinine is a nature product with AChE inhibitory activity. N-Methylcalycinine can be isolated from the roots of Stephania epigaea. N-Methylcalycinine can be used for the research of asthma, cancer, dysentery, fever, hyperglycemia, intestinal complaints, inflammation, sleep disturbances, tuberculosis and so on .
|
-
-
- HY-N0946
-
(-)-Pinoresinol 4-O-β-D-glucopyranoside
|
Glucosidase
|
Metabolic Disease
|
(-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC50 value of 48.13 µM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease .
|
-
-
- HY-P3841
-
|
PKC
|
Others
|
Protein Kinase C β Peptide is a peptide fragment of Protein Kinase Cβ. Protein Kinase Cβ is related with hyperglycemia decreases endothelium-derived nitric oxide. Inhibition of Protein kinase Cβ prevents the reduction in endothelium-dependent vasodilation induced by acute hyperglycemia .
|
-
-
- HY-149532
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-33 (compound 7c) is a potent α-glucosidase inhibitor (IC50: 2.39 μM) and can be used in the study of type 2 diabetes and hyperglycemia .
|
-
-
- HY-149533
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-34 (compound 7f) is a potent α-glucosidase inhibitor (IC50: 2.90 μM) and can be used in the study of type 2 diabetes and hyperglycemia .
|
-
-
- HY-N7912
-
(2S)-Pterosin A
|
Others
|
Metabolic Disease
|
Pterosin A is an orally active anti-diabetic agent. Pterosin A promotes glucose uptake, increases serum insulin, and improves hyperglycemia and glucose intolerance in diabetic mice. Pterosin A can be isolated from Pteridium aquilinum .
|
-
-
- HY-N2821
-
|
Glucosidase
|
Metabolic Disease
|
(+)-Afzelechin, isolated from rhizomes of Bergenia ligulata, is an alpha-glucosidase activity inhibitor with an ID50 (50% inhibition dose) value of 0.13 mM. (+)-Afzelechin can delay the absorption of carbohydrates in food to suppress postprandial hyperglycemia and hyperinsulinemia .
|
-
-
- HY-N12721
-
-
-
- HY-P4815
-
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
Prokineticin 2 Isoform 2 (human) is a hypothalamic neuropeptide. Prokineticin 2 Isoform 2 (human) decreases food intake and involves in thermoregulation and energy metabolism in rodents. Prokineticin 2 has the potential for the research of hyperglycemia, metabolic syndrome (MetS) and obesity .
|
-
-
- HY-161411
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-60 (Compound 5k) exhibits a competitive inhibitory efficacy against α-Glucosidase, with IC50 of 10.8 μM .
|
-
-
- HY-108743
-
|
Insulin Receptor
|
Endocrinology
|
Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes .
|
-
-
- HY-N3021
-
|
Endogenous Metabolite
|
Metabolic Disease
|
D-chiro-Inositol is an epimer of myo-inositol found in certain mammalian glycosylphosphatidylinositol protein anchors and inositol phosphoglycans possessing insulin-like bioactivity. D-chiro-Inositol is used clinically for the treatment of polycystic ovary syndrome (PCOS) and diabetes mellitus, which can reduce hyperglycemia and ameliorate insulin resistance .
|
-
-
- HY-14452
-
Fatostatin
Maximum Cited Publications
19 Publications Verification
125B11
|
Fatty Acid Synthase (FASN)
|
Cancer
|
Fatostatin (125B11), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin decreases the transcription of lipogenic genes in cells. Fatostatin possesses antitumor properties, and lowers hyperglycemia in ob/ob mice .
|
-
-
- HY-P3608
-
|
GCGR
|
Metabolic Disease
|
[Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .
|
-
-
- HY-147711
-
|
Glucosidase
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-1 (compound 33) is a potent α-amylase/α-glucosidase inhibitor with IC50s of 2.01, 2.09 µM for α-amylase and α-glucosidase, respectively. Kinetic studies predict that α-Amylase/α-Glucosidase-IN-1 has the potential of anti hyperglycemia .
|
-
-
- HY-Q40876
-
|
Calcium Channel
|
Metabolic Disease
|
BBT is an enhancer of impaired glucose-stimulated insulin secretion (GSIS). BBT exhibits anti-hyperglycemia activity, and protects β-cells from cytokine- or streptozotocin (STZ)-induced cell death in type 2 diabetes models. BBT acts function via cAMP/PKA and long-lasting (L-type) voltage-dependent Ca2+ channel/CaMK2 pathway .
|
-
-
- HY-14452A
-
125B11 hydrobromide
|
Fatty Acid Synthase (FASN)
|
Cancer
|
Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice .
|
-
-
- HY-108743R
-
|
Insulin Receptor
|
Endocrinology
|
Insulin degludec (Standard) is the analytical standard of Insulin degludec. This product is intended for research and analytical applications. Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes .
|
-
-
- HY-146225
-
|
Glucosidase
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-2 (compound 5) is a potent α-amylase and α-glucosidase dual inhibitor with IC50 values of 13.02, 13.09 µM for α-amylase and α-glucosidase, respectively. α-Amylase/α-Glucosidase-IN-2 has the potential for the research of diabetic complications .
|
-
-
- HY-N11728
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
2,7"-Phloroglucinol-6,6'-bieckol is an orally active dual α-amylase/α-glucosidase inhibitor with IC50 values of 6.94 μM and 23.35 μM respectively. 2,7"-Phloroglucinol-6, 6'-bieckol alleviates postprandial hyperglycemia in diabetic mice. 2,7"-Phloroglucinol-6,6'-bieckol can be used in diabetes research .
|
-
-
- HY-163005
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-43 (compound AS14) is an α-glucosidase inhibitor (IC50: 4.32 μM) with acute hypoglycemic activity. α-Glucosidase-IN-43 exhibits safety and in vivo efficacy, is nontoxic to normal mouse fibroblasts, and is able to rescue streptozotocin (HY-13753)-induced diabetic rats. α-Glucosidase-IN-43 can be used to study postprandial hyperglycemia in diabetic patients .
|
-
-
- HY-123797
-
|
SGLT
|
Metabolic Disease
|
KGA-2727 is a first selective, high-affinity and orally active SGLT1 inhibitor with Kis of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 has antidiabetic efficacy .
|
-
-
- HY-N9075
-
|
Glucosidase
|
Cancer
|
9-(4′-Hydroxyphenyl)-2-methoxyphenalen-1-one is a phytoalexin and mixed competitive α-glucosidase inhibitor of Bacillus stearothermophilus (IC50: 3.86 mg/L) .
|
-
-
- HY-147678
-
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
GPR40 agonist 5 (compound I-14) is an orally active and potent GPR40 (G protein coupled receptor 40) agonist, with an EC50 of 47 nM. GPR40 agonist 5 decreases the levels of blood glucose and improves the glucose tolerance. GPR40 agonist 5 has sufficient effectiveness for the control of hyperglycemia state in type 2 diabetic mice . GPR40 agonist 5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-100446
-
|
Glutaminase
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
|
NTU281 is a potent transglutaminase-2 inhibitor. NTU281 can reduce the increases in serum creatinine and albuminuria in diabetic rats. NTU281 can also reduce glomerular collagen I accumulation, Hic-5 and α-SMA expression, and apoptosis. NTU281 can be used for researching glomerulosclerosis caused by diabetes .
|
-
-
- HY-N0171B
-
β-Sitosterol (purity>75%); 22,23-Dihydrostigmasterol (purity>75%)
|
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Beta-Sitosterol (purity>75%) is a phytosterol with oral activity. Beta-Sitosterol (purity>75%) interferes with a variety of cell signaling pathways, including the cell cycle, apoptosis and cell proliferation. Beta-Sitosterol (purity>75%) has anti-inflammatory, antioxidant, and antitumor activities .
|
-
-
- HY-14728
-
R1439; RO0728804
|
PPAR
|
Metabolic Disease
|
Aleglitazar (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes .
|
-
-
- HY-B0457
-
Chlorimipramine hydrochloride; G-34586 hydrochloride; NSC-169865 hydrochloride
|
Serotonin Transporter
|
Neurological Disease
|
Clomipramine (Chlorimipramine) hydrochloride is a potent 5-HT reuptake blocker with the IC50 value of 1.5 nM. Clomipramine hydrochloride is a tricyclic antidepressant that can be used for the research of depression and obsessive compulsive disorder (OCD) .
|
-
-
- HY-B0457A
-
Chlorimipramine; G-34586; NSC-169865
|
Serotonin Transporter
|
Neurological Disease
|
Clomipramine (Chlorimipramine) is a potent 5-HT reuptake blocker with the IC50 value of 1.5 nM. Clomipramine is a tricyclic antidepressant that can be used for the research of depression and obsessive compulsive disorder (OCD) .
|
-
-
- HY-B0457AR
-
|
Serotonin Transporter
|
Neurological Disease
|
Clomipramine (Standard) is the analytical standard of Clomipramine. This product is intended for research and analytical applications. Clomipramine (Chlorimipramine) is a potent 5-HT reuptake blocker with the IC50 value of 1.5 nM. Clomipramine is a tricyclic antidepressant that can be used for the research of depression and obsessive compulsive disorder (OCD) .
|
-
-
- HY-B0457R
-
|
Serotonin Transporter
|
Neurological Disease
|
Clomipramine (hydrochloride) (Standard) is the analytical standard of Clomipramine (hydrochloride). This product is intended for research and analytical applications. Clomipramine (Chlorimipramine) hydrochloride is a potent 5-HT reuptake blocker with the IC50 value of 1.5 nM. Clomipramine hydrochloride is a tricyclic antidepressant that can be used for the research of depression and obsessive compulsive disorder (OCD) .
|
-
-
- HY-N2896
-
|
Reactive Oxygen Species
|
Inflammation/Immunology
|
Arjunolic acid is a saponin isolated from Cyclocarya paliurus and has various biologial activities, including antioxidant, antimicrobial, antibacterial and anti-inflammory activities. Arjunolic acid is also a potent antioxidant and plays an important role in the protection of cells and tissues against deleterious effects of reactive oxygen species .
|
-
-
- HY-10581
-
AM-1155; BMS-206584; PD135432
|
Bacterial
Topoisomerase
Antibiotic
|
Infection
|
Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
|
-
-
- HY-10581A
-
AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride
|
Bacterial
Topoisomerase
Antibiotic
|
Infection
|
Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
|
-
-
- HY-10581B
-
AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate
|
Bacterial
Topoisomerase
Antibiotic
|
Infection
|
Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.
|
-
-
- HY-10581C
-
AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate
|
Bacterial
Topoisomerase
Antibiotic
|
Infection
Inflammation/Immunology
|
Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis in vivo.
|
-
-
- HY-10581R
-
|
Bacterial
Topoisomerase
Antibiotic
|
Infection
|
Gatifloxacin (Standard) is the analytical standard of Gatifloxacin. This product is intended for research and analytical applications. Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-108743
-
|
Insulin Receptor
|
Endocrinology
|
Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes .
|
-
- HY-P3841
-
|
PKC
|
Others
|
Protein Kinase C β Peptide is a peptide fragment of Protein Kinase Cβ. Protein Kinase Cβ is related with hyperglycemia decreases endothelium-derived nitric oxide. Inhibition of Protein kinase Cβ prevents the reduction in endothelium-dependent vasodilation induced by acute hyperglycemia .
|
-
- HY-P4815
-
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
Prokineticin 2 Isoform 2 (human) is a hypothalamic neuropeptide. Prokineticin 2 Isoform 2 (human) decreases food intake and involves in thermoregulation and energy metabolism in rodents. Prokineticin 2 has the potential for the research of hyperglycemia, metabolic syndrome (MetS) and obesity .
|
-
- HY-P3608
-
|
GCGR
|
Metabolic Disease
|
[Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .
|
-
- HY-108743R
-
|
Insulin Receptor
|
Endocrinology
|
Insulin degludec (Standard) is the analytical standard of Insulin degludec. This product is intended for research and analytical applications. Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: